The combination therapy of atezolizumab (programmed death 1 inhibitor) plus bevacizumab (vascular endothelial growth factor antibody drug) for treating unresectable hepatocellular carcinoma (HCC) was introduced in 2020. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.